Rep. April McClain Delaney Sells Off Shares of Bio-Techne Corp (NASDAQ:TECH)

Key Points

• Representative April McClain Delaney disclosed the sale of Bio-Techne Corp (NASDAQ:TECH) stock valued between $1,001 and $15,000, indicating active financial moves within the biotechnology sector.
• Bio-Techne recently reported a quarterly revenue of $316.96 million, exceeding analyst expectations and reflecting a 3.6% year-over-year growth.
• The company announced a quarterly dividend of $0.08 per share with a payout ratio of 69.57%, showcasing its commitment to returning value to shareholders.

Representative April McClain Delaney (D-Maryland) recently sold shares of Bio-Techne Corp NASDAQ: TECH. In a filing disclosed on September 02nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on August 1st.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of BJ's Wholesale Club NYSE: BJ on 8/25/2025.
• Purchased $15,001 - $50,000 in shares of Markel Group NYSE: MKL on 8/21/2025.
• Sold $15,001 - $50,000 in shares of Dayforce NYSE: DAY on 8/19/2025.
• Sold $1,001 - $15,000 in shares of Viking NYSE: VIK on 8/13/2025.
• Sold $15,001 - $50,000 in shares of Core & Main NYSE: CNM on 8/11/2025.
• Purchased $1,001 - $15,000 in shares of Jones Lang LaSalle NYSE: JLL on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 8/7/2025.
• Sold $1,001 - $15,000 in shares of IDEXX Laboratories NASDAQ: IDXX on 8/7/2025.
• Sold $1,001 - $15,000 in shares of Clean Harbors NYSE: CLH on 8/7/2025.
• Purchased $15,001 - $50,000 in shares of Morningstar NASDAQ: MORN on 8/2/2025.

Bio-Techne Stock Performance

Shares of TECH stock traded up $1.49 on Friday, reaching $54.41. The stock had a trading volume of 1,745,308 shares, compared to its average volume of 1,832,320. The firm has a market capitalization of $8.53 billion, a price-to-earnings ratio of 118.29, a P/E/G ratio of 3.47 and a beta of 1.47. The company has a quick ratio of 2.38, a current ratio of 3.46 and a debt-to-equity ratio of 0.18. Bio-Techne Corp has a 12 month low of $46.01 and a 12 month high of $80.95. The firm's 50-day moving average is $53.90 and its two-hundred day moving average is $53.71.

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The firm had revenue of $316.96 million for the quarter, compared to analysts' expectations of $315.14 million. Bio-Techne had a net margin of 6.02% and a return on equity of 13.43%. The business's revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.49 EPS. On average, research analysts expect that Bio-Techne Corp will post 1.67 EPS for the current fiscal year.

Bio-Techne Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, August 29th. Stockholders of record on Monday, August 18th were issued a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Bio-Techne's dividend payout ratio is presently 69.57%.

Hedge Funds Weigh In On Bio-Techne

Several large investors have recently modified their holdings of the business. Comerica Bank raised its stake in Bio-Techne by 0.9% during the fourth quarter. Comerica Bank now owns 56,964 shares of the biotechnology company's stock worth $4,103,000 after buying an additional 498 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in Bio-Techne by 7.2% in the fourth quarter. Ameriprise Financial Inc. now owns 4,702,942 shares of the biotechnology company's stock worth $338,756,000 after purchasing an additional 317,349 shares during the period. BNP Paribas Financial Markets grew its holdings in Bio-Techne by 61.8% in the fourth quarter. BNP Paribas Financial Markets now owns 281,747 shares of the biotechnology company's stock worth $20,294,000 after purchasing an additional 107,667 shares during the period. Bayesian Capital Management LP acquired a new position in shares of Bio-Techne during the fourth quarter valued at about $821,000. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Bio-Techne during the fourth quarter valued at about $3,390,000. Institutional investors own 98.95% of the company's stock.

Analysts Set New Price Targets

Several research firms recently issued reports on TECH. Benchmark reiterated a "buy" rating and set a $75.00 price target on shares of Bio-Techne in a research report on Thursday, June 5th. Royal Bank Of Canada upgraded shares of Bio-Techne from a "hold" rating to a "moderate buy" rating in a research report on Wednesday. Stephens upgraded shares of Bio-Techne to a "strong-buy" rating and set a $65.00 price target on the stock in a research report on Tuesday, July 22nd. Scotiabank reduced their price target on shares of Bio-Techne from $90.00 to $75.00 and set a "sector outperform" rating on the stock in a research report on Friday, July 11th. Finally, TD Cowen began coverage on shares of Bio-Techne in a research report on Wednesday, July 9th. They set a "buy" rating and a $65.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Bio-Techne has an average rating of "Moderate Buy" and an average target price of $70.42.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.